Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab ; volume:10 ; number:1 ; day:23 ; month:10 ; year:2012 ; pages:1-13 ; date:12.2012
Journal of translational medicine ; 10, Heft 1 (23.10.2012), 1-13, 12.2012
- Urheber
-
Fountzilas, George
- Beteiligte Personen und Organisationen
-
Christodoulou, Christos
Bobos, Mattheos
Kotoula, Vassiliki
Eleftheraki, Anastasia G.
Xanthakis, Ioannis
Batistatou, Anna
Pentheroudakis, George
Xiros, Nikolaos
Papaspirou, Irene
Koumarianou, Anna
Papakostas, Pavlos
Bafaloukos, Dimitrios
Skarlos, Dimosthenis V.
Kalogeras, Konstantine T.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-10-212
- URN
-
urn:nbn:de:1111-2016041440331
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fountzilas, George
- Christodoulou, Christos
- Bobos, Mattheos
- Kotoula, Vassiliki
- Eleftheraki, Anastasia G.
- Xanthakis, Ioannis
- Batistatou, Anna
- Pentheroudakis, George
- Xiros, Nikolaos
- Papaspirou, Irene
- Koumarianou, Anna
- Papakostas, Pavlos
- Bafaloukos, Dimitrios
- Skarlos, Dimosthenis V.
- Kalogeras, Konstantine T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer